Alpaca SingleB® VHH Discovery Service
Compared with conventional IgG molecules, VHH antibodies that derive from camelid heavy chain only antibodies (HCAbs) possess many unique and favorable properties of size, solubility, stability, immunogenicity, recognition of uncommon or hidden epitopes, format engineering and manufacturability, and have manifested medical potential both as diagnosis reagents and in therapeutic drug development.
Phage display is the dominant approach for VHH antibody discovery. Unfortunately, its capability is heavily subject to antibody expression bias, protein folding errors, low screening efficiency, and loss of diversity.
DetaiBio alpaca SingleB® VHH discovery platform is an excellent alternate. Armed with our SmartFlow® FACS mAb Discovery platform and DeepLight® screening technology, DetaiBio R&D team is experienced in providing SingleB® Alpaca VHH antibody fast discovery service: we are able to deliver certain amount of unique, FACS-validated VHH antibody candidates as fast as 90 days after 1st immunization shot. Similar with our cases of other host species, before us losing them, both memory B cells and plasma cells are directly screened to cover most B cell clones, thus guaranteeing maximal CDR diversity of antibody hits.
VHH Features
Conventional antibody
150kDa
Camelid heavy-chain antibody
95kDa
Fv
30kDa
scFv
30kDa
dsFv
30kDa
Nanobody
12-14kDa
Based on its structural specificity, VHH integrates the advantages of traditional antibodies and small molecule drugs:
- Low Molecular Weight: only 12-14 kda with strong tissue penetration, widely used in tumor diagnosis and treatment and molecular imaging.
- Simple Structure: easy to carry out genetic engineering transformation, with 80% homology with human VH and easy to humanize.
- Low Immunogenicity: no FC tail end, which will not cause related immunogenicity, and has high pharmaceutical properties.
- High Specificity: long CDR3 region , which can form a finger shaped convex ring to further identify hidden antigen epitopes.
- High Hydrophilicity: hydrophilic amino acids in FR2 area ensure water solubility, and antibodies are not easy to aggregate.
- Simple Preparation: it can be expressed in large quantities, and the industrial scale-up production cost is low and the cycle is short.
- High Stability: it is easy to store and can withstand high temperature, strong acid, strong alkali and other mutagenic conditions.
Service Features
90-day High Delivery
Deliver 50 FACs binders
& VHH sequence
“1+1”Double Guarantee
PBC&MBC
double screening, double guarantee
Pre-function Screening
DeepLight® Platform
with multiple on-chip assay
Natural Maturation
Higher antibody affinity
Basically eliminate immunogenicity
Procedure
Workflow
| Stage | Service | Timeline | Deliverables |
|---|
| Stage Ⅰ Animal Immunization | - Antigen preparation (optional)
- Animal immunization
- Serum titer test
| 8-9 weeks | Premium Package- FACs binders ＞50
- Ensure sequence diversity
- Antibody sequence and expression plasmid
- CoA
Economic Package - 5-10 ELISA positive clones
- Antibody sequence and expression plasmid
- Select one strain purified 1 mg antibody
- CoA
|
| Stage Ⅱ “1+1”Double Screening | - MBC screening
- PBC screening
| 1 day |
| Stage Ⅲ BGE® HTP Expression & Functional Test | | 1-2 weeks |
| Stage Ⅳ Monoclonal Antibody Gene Sequencing | | 1 week |
Stage Ⅴ
Expression and Purification of Recombinant Antibody (optional) | - Transfection level plasmid preparation
- Transient transfection expression
- HTP purification
- Endotoxin control
| For enquiry |
Related Service
